This biotech could have a major cancer breakthrough on the cards
Published: Mon, 09/11/17
 SMS alerts can make the difference between a profitable trade and a missed opportunity. Text “MOMO” to 555888 to receive our instant, reliable and free SMS alerts. Traders and Investors, We've got something a little different to kick things off this week... A hot Nasdaq play lined up for today's trading session. Let's start with the technicals. OncoSec Medical, Inc (ONCS) has had a volume explosion in recent days with some very solid news catalysts. The chart is showing a classic double bottom at around $0.90, which it touched in May and August. And true to this bullish chart pattern, it has bounced off this support well breaking through its 50 and 100 day moving averages, touching $1.18 on Thursday. There could be much more upside to come now. With a recent high of $1.37 in June, a six month high of over $1.40, and a 12 month high of $2.08, there is plenty of gains to shoot for. Check out this chart, you'll see what I mean...  About ONCS ONCS is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response. ImmunoPulse® IL-12, OncoSec's lead program, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com Recent Major Appointments OncoSec Appoints Industry Leader Daniel J. O'Connor to its Board of Directors ONCS announced the appointment of Daniel J. O'Connor to its Board of Directors. Mr. O'Connor brings more than 20 years of successful financing and licensing experience to OncoSec's Board of Directors, most recently serving as President and Chief Executive Officer of Advaxis Immunotherapies. His appointment to the Company's Board is effective immediately. Mr O'Connor, Former President and CEO of Advaxis Immunotherapies and Senior Vice President of ImClone Systems will add significant biopharma clinical, regulatory, business development, and fundraising expertise to ONCS. OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors Last week ONCS also announced the appointment of Annalisa Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc. (DMTX), to its Board of Directors. Dr. Jenkins brings over 25 years of global industry experience to OncoSec's Board of Directors with a wealth of knowledge in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Her election to the Company's Board is effective immediately. Dr Jenkins, Former Head of Global Research and Development for Merck Serono and Head of Global Medical Affairs of Bristol-Myers Squibb, brings biopharma drug development, fundraising and M&A experience to ONCS. In Summary... ONCS has seen major recent volume come in after big news catalysts, and has a bullish double bottom chart formation. ONCS recently broke through its 50 and 100 day moving averages, and with a 12 month high of over $2, there is plenty of upside to aim for. We urge you to do your research on ONCS immediately, and be ready to trade come this morning. --------------------------------------------------------------------------------------------------------
Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity. Disclaimer Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here. SmallCapMomo.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SmallCapMomo.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. SmallCapMomo.com does not offer such advice or analysis, and SmallCapMomo.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, SmallCapMomo.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SmallCapMomo.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SmallCapMomo.com is not responsible for any claims made by the companies advertised herein. SmallCapMomo.com may receive compensation and they, its employees and/or affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in SmallCapMomo.com statements and opinions and such statements and opinions cannot be considered independent. SmallCapMomo.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, SmallCapMomo.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. SmallCapMomo.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to close positions they have entered into at any given time including before or after the release of the companies profile. SmallCapMomo.com has been compensated three thousand dollars via electronic transfer from a non-affiliated third party ALG Financial for the profile of ONCS. SmallCapMomo.com does not accept compensation in restricted or free-trading shares for its marketing services of the company being profiled. However the third party that has compensated SmallCapMomo.com may hold free-trading shares of the company being profiled and could very well be selling shares of the company’s stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If SmallCapMomo.com ever does accept compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the position of those free trading shares received as compensation for our services at the time our promotional material is released to the public, as well as information on our intention to sell these shares during the promotional period or thereafter. Text MOMO to 555888. You will receive auto-dialed text alerts from SmallCapMomo.com. No consent req'd for purchase. Msg & data rates may apply. Msg frequency varies. Reply STOP to stop, HELP for help. |